WEHI scientists discovered a drug that blocks long COVID in mice and may improve acute treatment options beyond current antivirals like Paxlovid.

• WEHI researchers have developed a drug compound that protects mice from developing symptoms of long COVID.

• This groundbreaking study also showed that the compound treats acute COVID more effectively than Paxlovid, the current leading approved treatment.

• Researchers hope these results will pave the way for clinical trials and eventually lead to an oral treatment for long COVID.